Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) EPS (Basic) (2020 - 2025)

Ovid Therapeutics' EPS (Basic) history spans 6 years, with the latest figure at $141.83 for Q4 2025.

  • For Q4 2025, EPS (Basic) fell 40.37% year-over-year to $141.83; the TTM value through Dec 2025 reached -$91.05, down 125.61%, while the annual FY2025 figure was -$232.47, 62729.73% down from the prior year.
  • EPS (Basic) reached $141.83 in Q4 2025 per OVID's latest filing, up from -$168.01 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $237.84 in Q4 2024 to a low of -$728.12 in Q4 2023.
  • Average EPS (Basic) over 5 years is -$23.16, with a median of -$0.18 recorded in 2021.
  • Peak YoY movement for EPS (Basic): tumbled 454975.0% in 2023, then surged 65694.44% in 2024.
  • A 5-year view of EPS (Basic) shows it stood at -$0.37 in 2021, then soared by 56.76% to -$0.16 in 2022, then crashed by 454975.0% to -$728.12 in 2023, then surged by 132.66% to $237.84 in 2024, then plummeted by 40.37% to $141.83 in 2025.
  • Per Business Quant, the three most recent readings for OVID's EPS (Basic) are $141.83 (Q4 2025), -$168.01 (Q3 2025), and -$64.73 (Q2 2025).